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Abstract: Extracellular vesicles are a heterogeneous group of cell-derived membranous structures
comprising of exosomes, apoptotic bodies, and microvesicles. Of the extracellular vesicles, exosomes
are the most widely sorted and extensively explored for their contents and function. The size
of the nanovesicular structures (exosomes) range from 30 to 140 nm and are present in various
biological fluids such as saliva, plasma, urine etc. These cargo-laden extracellular vesicles arise
from endosome-derived multivesicular bodies and are known to carry proteins and nucleic acids.
Exosomes are involved in multiple physiological and pathological processes, including cellular
senescence. Exosomes mediate signaling crosstalk and play a critical role in cell–cell communications.
Exosomes have evolved as potential biomarkers for aging-related diseases. Aging, a physiological
process, involves a progressive decline of function of organs with a loss of homeostasis and increasing
probability of illness and death. The review focuses on the classic view of exosome biogenesis, biology,
and age-associated changes. Owing to their ability to transport biological information among cells,
the review also discusses the interplay of senescent cell-derived exosomes with the aging process,
including the susceptibility of the aging population to COVID-19 infections.
Keywords: exosomes; aging; extracellular vesicles; miRNA; COVID-19
1. Introduction
Extracellular vesicles (EVs), once considered to be cellular waste products with minimal biological
or clinical significance, have evolved over time to be one of the critical mediators of intercellular
communications, biomarkers for various diseases, and biovesicles for drug delivery and therapy.
Extracellular vesicles are lipid bound and are secreted by different type of cells. They form a
heterogeneous group comprising mainly of exosomes, microvesicles, and apoptotic bodies [1]. They are
grouped based on their size, biogenesis, composition, and function. The size of microvesicles is
approximately 100–1000 nm in diameter and they originate from the outward budding of the plasma
membrane. The apoptotic bodies are generated by the blebbing of plasma membrane of cells undergoing
apoptosis and the size ranges from 100 to 5000 nm [2,3]. Of the various EVs, exosomes are the smallest
(30–140 nm) and the most extensively studied [4]. The membrane bound vesicles are secreted by almost
all cell types and have been isolated from mucosal and endogenous biofluids such as blood, urine,
tears, lymph, gastric acid, breast milk, and saliva [5]. Although EVs vary in their origin, biogenesis,
secretion, targeting, and final fate [6,7], they have been implicated in key processes such as growth and
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development, cell-to-cell communication, immunomodulation, blood coagulation, aging, and various
pathologies [8].
The plasma membrane-derived lipid bilayer of EVs protects within it a diverse cargo of nucleic
acids, proteins, and lipids, and they are shielded against degrading enzymes such as nucleases and
proteases [9]. These cargos are stable under physicochemical conditions generally considered adverse
for biological materials. Moreover, the composition of the EVs represents a snapshot of the cell status
at the time of secretion, and studies have reported that pathological states such as cancer, premature
senescence, oxidative stress, and apoptosis could alter their composition [10].
2. Microvesicles and Apoptotic Bodies
All microvesicles (MVs) have specific ‘marker proteins’ regardless of the cell type from which they
are released. Since they are formed by the outward blebbing of the plasma membrane, they mainly
consist of cytosolic and plasma membrane-associated proteins such as tetraspanins, cytoskeletal
proteins, integrins, and heat shock proteins [6]. MVs target or interact with other cells with the help of
glycan-binding proteins on their surface [2]. MVs have the ability to package active cargo (such as
nucleic acids, proteins, and RNAs) and deliver it to neighboring cells and can thereby modulate/regulate
their function [11,12]. The cargo varies depending on the physiological or pathological state of the cells.
Some MVs released by Mesenchymal Stem Cells (MSCs) in response to oxidative stress could also
carry mitochondrial particles along with mitochondrial DNA (mtDNA) [13]. Perhaps understanding
the composition of MVs could aid in better therapeutic strategies.
Apoptotic bodies are released by dying cells, and they tend to be on the larger side (1–5 µm) based
on the size of various EVs [6]. The apoptotic bodies have a very different composition compared to MVs
and exosomes. They majorly contain intact organelles, chromatin, histones, and glycosylated proteins.
3. Exosomes: Biogenesis and Release
‘Platelet dust’ was the term used for the first time to describe EVs by Wolf [14]. Thereafter,
all biological fluids were found to contain vesicles of different sizes [7]. The smallest of all the EVs (less
than 150 nm), the exosomes were first visualized in the reticulocytes of rat and sheep [15]. The vesicle
release was considered as a mechanism for the elimination of specific membrane proteins like transferrin
receptors, which are known to diminish during the maturation of reticulocyte [15]. The exosomes are
released during the fusion of microvesicular bodies (MVBs) with the plasma membrane [6]. The release
of exosomes has many steps involved such as (i) the formation of intraluminal vesicles in MVBs,
(ii) their transport to plasma membrane, and (iii) fusion (Figure 1). Normally, MVBs help in clearing
cellular waste by undergoing degradation in the lysosomes. To some extent, the composition of
exosomes reflects the composition of MVBs. Hence, exosomes could also carry misfolded and harmful
proteins and can contribute to disease progression [16].
Various studies have demonstrated different strategies for the biogenesis of exosomes. One of
the broadly accepted strategies is the involvement of the Endosomal Sorting complex required for
transport (ESCRT). ESCRT is activated during membrane budding, cytokinesis, and autophagy, and it
is involved in EV biogenesis [1]. The exosome biogenesis can occur either via ESCRT-dependent or
ESCRT-independent pathways and mainly depends on the type and physiological state of the cell.
In addition, the biogenesis pathways will also determine the composition of various exosomes [17].
Figure 1 illustrates the many different proteins involved in the exosome biogenesis.
Exosomes released from different cell types contain different lipids and proteins. The lipid
composition of exosomes comprises those lipids that are part of the plasma membrane and the Golgi,
and they are enriched in glycosphingolipids, cholesterol [18], phosphatidylserine [19], and ceramide.
Exosomal cargo also includes RNAs such as mRNAs, miRNAs, LncRNAs, and circular RNAs as well as
short DNA sequences. These cargos are potential mediators of cell survival, homeostasis, cell functions,
and intercellular communications. Put together, these distinct characteristics position EVs as a potential
class of biomarkers with strong diagnostic potential in the context of personalized medicine.
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Exosomes have been implicated in a variety of biological processes. Dendritic cell-derived
exosomes have been shown to modulate T-cell response similar to the intact cells, thus implicating an
immunomodulatory role for these nanovesicles [20]. Exosomes with hsc73, a heat shock protein, have
been reported to elicit antitumor activity [21]. The FasL ligand in exosomes from tumor cells has been
shown to mediate apoptosis [22]. The composition and the function of the exosomes vary depending
on the cell type and reflects their pathophysiological state. Depending on the protein composition,
the exosomes may have varied effects such as cytotoxic, immunomodulatory, and apoptotic activity.
Exosomes help transfer membrane proteins between cells without the requirement of direct cell–cell
contact [23].
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Figure 1. Exosome biogenesis and secretion. The biogenesis of exosomes is mediated by
either ESCRT-dependent or ESCRT-independent pathways. ESCRT pathways involve numerous
proteins/enzymes. Multivesicular bodies fuse with the ce ll membrane and result in the release
of exosomes. (SIMPLE: Small Integral Membrane Protein of the lysosome/late endosome; MVB:
Microvesicular Bodies; ESCRT: Endosomal Sorting complex required for Transport; Hrs: Hepatocyte
growth factorregulated tyrosine kinase substrate; STAM: Signal Transducing adaptor Molecule; TSG101:
Tumor susceptibility gene 101; VSP4B: Vacuolar Protein Sorting 4 Homolog B).
4. Senescence and Its Effect on Stem Cell Biology, Transplantation, and Function
Aging is a complex cellular and molecular process involving both genetic and environmental factors.
The salient features of aging include elevated Reactive Oxygen Species (ROS) levels, mitochondrial
dysfunction, genetic mutations, and DNA damage [24]. With aging, inflammation and macromolecule
dysfunction slowly sets in, leading to irreversible damage/senescence of cells [25]. Mitochondrial
dysfunction is the major reason for the increased oxidative stress. Adult stem cells have also been
shown to exhibit senescent phenotype with increasing age [26,27]. These pathological changes increase
the burden on cells, which will ultimately succumb to apoptosis. Studies have shown that a reduction of
senescent cells can lead to reduced inflammation, macromolecular dysfunction, and an improvement in
progenitor functions [28]. The aging process can be driven by cell autonomous or cell non-autonomous
mechanisms. The time-dependent accumulation of damaged macromolecules, genetic material,
and organelles can lead to cell autonomous aging [29]. However, studies have shown that circulating
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factors in younger healthy animals could regenerate the tissues in older mice. Factors such as Growth
Differentiation Factor 11 (GDF-11) and oxytocin are some examples and are termed anti-geronic [30].
For instance, recombinant GDF (rGDF) has rejuvenating effects in heart, skeletal muscles, and brain [31].
Conversely, some factors in blood from old patients have been shown to drive aging. Pro-geronic
factors such as chemokine CCL-11 and β2 microglobulin could play roles in cell non-autonomous
aging [32]. Since EVs are released by all cells, they could act both as anti- and pro-geronic factors.
Senescence involves the loss of the proliferative potential of normally replication-competent
cells. Senescent cells usually develop a senescence-associated secretory phenotype (SASP) and
are characterized by an increased release of pro-inflammatory cytokines and chemokines,
and tissue-damaging proteases [33]. They also released factors that can alter stem and progenitor
cell function, hemostatic factors, and growth factors. The markers of senescent cells are an increased
expression of cell cycle regulators like p16INK4A and p21Cip1. [34,35]. They also have increased SASP
factors such as IL-6, IL-8, monocyte chemoattractant protein-1, and plasminogen-activated inhibitor-1,
increased senescence-associated β-galactosidase (SA-βgal) activity and telomere-associated DNA
damage foci (TAFs) [36]. These SASP features have substantial pathological effects to the neighboring
cells. Studies found that removal of the p16INK4a-positive cells and also clearing senescent cells
extend the lifespan in transgenic mice models [37]. On the contrary, injecting senescent cells could
drive age-related diseases, indicating the critical role played by these cells in determining the physical
condition [38]. Senescent cells have been reported to release more EVs than normal cells, and they
exhibit a totally different composition [39]. These EVs could also be considered part of the SASPs and
could play role in senescent cell-induced premature aging.
Another effect of aging is the loss of ability of cells to effectively respond to stress and their limited
regenerative capacity. Several studies have reported an age-dependent decline in the characteristics of
several different types of adult stem cells [40]. Mesenchymal Stem Cells (MSCs) from old mice have
been shown to be defective in differentiation [41]. Interestingly, injecting young MSCs into old mice
has shown to expand the lifespan [42].
The bone marrow and adipose tissue-derived MSCs were found to have reduced ability to
respond to oxidative stress when isolated from aged donors [43]. MSCs are a key component of the
hematopoietic niche and with aging, MSCs exert a detrimental effect on the hematopoietic system.
Neural stem cells exhibit compromised proliferation and differentiation as well as an enhanced
senescence phenotype with aging [44]. Age-associated cognitive effects such as neurodegenerative
disorders, memory defects, and olfactory dysfunction were consequent to the deterioration of NSC
function. The function of the HSCs is modulated by the microenvironment, which produces the
cell-intrinsic and extrinsic factors [45]. However, aging impairs the microenvironment, which alters
HSC functions, similar to cell cycle regulation, proliferation, and differentiation. c-kit+ Cardiac Stem
Cells (CSCs) residing within the myocardium also exhibit age-associated changes. CSCs from aged
patients expressed the cyclin-dependent kinase p16INK4a [46]. CSCs from older mice had reduced
telomere length and increased apoptosis [47]. The same changes were observed in Wistar rats with
aging and researchers also found that the incidence of hypertensive heart disease accelerated the aging
process [27].
Several studies indicate the protective effect of EVs from stem/progenitor cells. For instance,
EVs from MSCs have been shown to have the ability to repair damaged tissues and can induce healing
of liver, kidney, and heart [48,49]. Therefore, one could assume that EVs from senescent cells would
have detrimental effects. The EVs act as messengers by delivering their cargo to the target cells and
could explain their role as potential pro- and anti-geronic factors.
Cellular aging could also influence the transplantation outcomes. Age-associated changes in the
stem cells and how agingimpairs their functional ability are now well understood. Hence, the age of the
donor and the recipient are of prime importance during stem cell transplantation. The stem cells from
a young recipient could rejuvenate whereas those from an aged donor exert tissue dysfunction [50].
In addition, the recipients’ microenvironment modulates the fate of stem cells being transplanted.
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When hematopoietic stem cells (HSCs) from old mice were transplanted, they exhibited reduced
rates of homing and engraftment along with impaired differentiation ability [51]. When performing
hematopoietic cell transplantation, it is critical to assess the chronological as well as biological age
of the patient. The biological age of the cells can be attained by evaluating their clonogenic capacity
and telomere length [52]. The telomere length of autologous CD34+ cells did not have any influence
on the clinical outcome in cardiomyopathy patients. However, a higher CD34+ human Telomerase
reverse Transcriptase (hTERT) expression was associated with better clinical outcome [53]. A study
found that the increasing age is associated with low peripheral blood CD34+ cells and diminished
bone marrow stem cell mobilization by Granulocyte Colony Stimulating Factor (GCSF) in ischemic
heart failure patients [54]. EVs secreted from both the transplanted and recipient cells could modulate
the cellular behavior and modify signaling pathways. EVs from young stem cells were found to
have higher amounts of galectin-3 and certain miRNAs that promote stem cell function compared to
those from senescent cells [55]. EVs from senescent cells accelerated age-associated processes such as
inflammatory gene expression and telomere dysfunction.
5. Role of Extracellular Vesicles in Age-Related Diseases
Aging is an independent risk factor in the development of neurodegenerative disorders,
cardiovascular disease, and diabetes, which are the primary causes of mortality and morbidity
in the elderly population [56]. Most recently, with regard to the COVID-19 (Coronavirus disease 2019)
pandemic, the aging/elderly population is known to be extremely vulnerable to the disease, resulting
in a higher fatality rate [57–59]. Age-related changes occur at the cellular and molecular level, affecting
the physiological function of tissues and organs. The senescent cells are characterized by cell growth
arrest and altered differentiation functions [60]. All these changes result from the cumulative effect of
many signaling pathways regulating different cellular processes in the cell. The accumulating evidence
suggests that exosomes are physiologically relevant intercellular messengers [6]. Senescence-associated
exosomes could transfer many molecules and could accelerate the aging process or associated
pathologies in an autocrine, paracrine, and endocrine fashion [61] (Figure 2). A study was carried
out to understand the premature cellular senescence and alterations in exosome biogenesis during
irradiation in human prostate cancer cells. This analysis identified a novel connection between the
induction of p53-dependent senescence and the release of exosomes [61]. Importantly, this supports the
possibility that senescence-associated exosomes can transfer cargos between cells that may be recruited
to increase the exosome release observed during cellular senescence. EVs from older individuals
were shown to have MHC-II expression on monocytes, which was indicative of the effect of EVs on
modulating immune response [62]. These EVs are taken up faster by B cells in older individuals when
compared to young, and as a result, the levels of circulating EVs could be reduced. This is in contrast
to the observation of increased EV production in aged cultured cells [29].
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Figure 2. Age-related complications of senescent cell derived exosomes. Extracellular vesicles (EVs)
secreted from senescent cells have been implicated in cardiovascular diseases, diabetes, neurological
disorders, and vascular aging. Senescent EVs modulate several different proteins and miRs, thus
exacerbating age-associated pathologies.
6. Neurodegenerative Disorders
In neurodegenerative diseases such as age-related macular degeneration (AMD) and Alzheimer’s
disease (AD), exosomes have been implicated [63]. The contribution of extracellular vesicles (EVs)
to peripheral inflammation during aging is also reported [64]. A previous study involving young
and old Wistar rats suggests that the normal aging process adversely changes the profile of central
and circulating extracellular vesicles. The study aimed at determining the protein concentration,
CD63 content, along with AChE activity, in plasma and Cerebrospinal Fluid (CSF) from 3- and
21-month-old Wistar rats [65]. This study correlates the systemic inflammation widely described in the
aging process and the susceptibility to age-related diseases such as atherosclerosis and diabetes. During
the process of physiological aging, chronic inflammation characterized by increased pro-inflammatory
cytokines ensues. The study evaluates exosomal inflammatory cytokines in the healthy aging process.
The study concluded that healthy aging changes circulating EV profile in rodents with significant change
in the expression of exosomal marker such as CD63 and Acetylcholinesterase (AChE) activity [65].
Platelet derived EVs also carry cytokines, such as IL-1β and inflammasome components in the synovial
fluid, as evidenced in patients with rheumatoid arthritis [66]. Interestingly, EVs from the plasma of aged
rats show reduced IL-1β levels, which is consistent with the exosome profile in inflammatory condition
such as rheumatoid arthritis [25]. The altered IL-1β levels in circulating EVs can be linked to age-related
inflammatory conditions. In addition, the disruption of the CSF exosomes as assessed by lower
CD63 levels can be related to susceptibility to neurodegenerative disorders in the elderly. It has been
observed that the EVs in most inflammatory diseases carry within them damage-associated mediators,
cytokines, autoantigens, and tissue-degrading enzymes [67]. Endothelial toxins such as Aβ40 and Aβ42
were observed in the plasma endothelial-derived exosomes of patients with Alzheimer’s disease [68].
Activated microglia could mediate neuroinflammation in various neuropathologies such as Parkinson’s
Cells 2020, 9, 1974 7 of 17
disease [69]. Misfolded alpha-synuclein (α-syn) can further induce misfolding of the α-syn, leading to
protein aggregation in neurons, thereby mediating inflammation. Studies have found that α-syn can
spread between neurons through exosomes [70]. Astrocytes-derived exosomes have also been shown
to induce protein aggregation in the brain [71].
7. Cardiovascular Disorders
A general feature of cellular senescence is increased EVs secretion [29]. Various stimuli such as
serial passaging, senescence, and cell damaging processes such as irradiation and DNA-damaging
reagents enhance EVs secretion [36]. A recent study on microvesicles from the plasma of senescent
Endothelial Cells (ECs) promoted the calcification of human aortic smooth muscle cells [11]. A previous
study has reported the presence of senescent ECs in human atherosclerotic plaque [11], suggesting
a specific role of senescent MVs in plaque development. Along with oxidative stress, endothelial
dysfunction, and inflammation, senescence-associated MVs are considered to be a significant contributor
to the development of atherosclerosis [39]. The number of MVs in plasma increases with aging,
and they also contain increased amounts of calcium and calcium-binding proteins involved in the
calcification of the vessels [72]. Hence, MVs could be used as biomarkers of calcium mineral deposits.
MVs might serve as a therapeutic target for the age-associated CVDs such as atherosclerosis, and their
quantification and evaluation will help identify patients at risk of CVDs. EVs from senescent cells can
mediate early senescence in the neighboring target cell. For instance, EVs from patients with acute
coronary syndrome developed early endothelial dysfunction, oxidative stress, premature senescence,
and thrombogenicity [73]. miRNAs involved in pathophysiological conditions of the heart are mostly
packaged and transported via exosomes [74]. For instance, miR-21 levels were significantly high in
patients with aortic stenosis [75]. During heart failure, miR-1, miR-133, miR-208, and miR-499 were
found to be enriched in cardiac muscle [76]. Other miRNAs such as miR-1 and miR-133a are also
elevated in other cardiovascular diseases [77]. In vitro experiments have shown that cardiac fibroblasts
release miRNA-enriched exosomes and facilitate the expression of genes involved in hypertrophy [78].
Next-generation RNA sequencing found that the miRNAs of the exosomes in hypertensive rats
were differentially altered compared to normal rats, mainly in relation to the hypertension-specific
signaling pathways [79]. The studies indicate that the selective packaging of miRNAs in exosomes
under pathological condition could facilitate the development of better diagnosis and treatment for
cardiovascular diseases.
8. Diabetes
Diabetes mellitus (DM) is a commonly occurring metabolic disorder whose incidence increases
with aging. Initial studies have found elevated levels of different cell-derived large extracellular vesicles
in individuals with diabetes mellitus. EVs derived from endothelial cells, monocytes, and platelets
could be used as a biomarker for DM [80]. However, cell-specific differences in EV production have
been reported in diabetes. For instance, erythrocyte-derived EVs were higher, whereas EVs from
platelets and leukocytes were not significantly different in diabetic individuals [81]. Several factors such
as insulin resistance, body composition, inflammation, diets, drug, and exercise could induce a higher
production of EVs in hyperglycemic condition. The diabetic condition also affects the composition of
exosomes [82]. EVs from diabetic patients have been found to express lower levels of leptin receptors
and phospho-insulin receptors [81].
A study by Wu et al. on EVs from diabetic patients found that they have altered cargo and
modulated the morphology and migration of endothelial cells compared to EVs from euglycemic
individuals. Chemoattractants such as Vascular Endothelial Growth Factor A (VEGF-A) present in this
cargo induce proangiogenic behavior in endothelial cells. These EVs also have inflammatory proteins
such as CD40 and HGF, which could have a protective effect in diabetic individuals [83]. EVs play
a significant role in contributing to the development of diabetic cardiomyopathy. EVs derived from
the cardiomyocytes of diabetic rats expressed higher levels of miR-320 and low levels of miR-126 [84].
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These miRs modulate endothelial cell functions such as proliferation, migration, and tube formation.
Hsp70-containing EVs from diabetic rats inhibited cardiomyocyte proliferation which otherwise
exhibited protection [85]. Another protein from diabetic endothelial EVs, Mst1, promoted the apoptosis
of cardiomyocytes [86]. Rats fed with a high-fat diet exhibited increased circulating microvesicles,
which had pro-inflammatory effects on endothelial cells [87]. These studies indicate that the intercellular
transfer of harmful molecules of EVs between cardiac cells could deteriorate diabetic cardiomyopathy.
Adipokines are biologically active molecules secreted by adipose tissue, and their alterations could
lead to metabolic disorders. The dysregulation of adipocyte secretome is linked to the pathophysiology
of type-2 diabetes, and this secretome was mostly associated with the exosomes [88]. The exosomes
derived from adipocytes primarily act as regulators of inflammation and systemic insulin resistance.
In obesity, the altered adipokine composition contributes to the development of metabolic disorders [89].
Adipocytes release fatty acids and other lipids to meet the systemic metabolic needs, and these bioactive
molecules are packaged in exosomes. These lipids are transported to local macrophages. The lipid
content in the exosomes from obese mice was much higher than that from the lean mice [90]. In pregnant
women with preeclampsia or gestational diabetes mellitus, the concentration of placenta-derived
exosomes was found to be higher [91]. These observations indicate the role that exosomes play in
regulating metabolic disorders.
9. Other Age-Related Pathologies
Vascular aging involves phenotypic and structural changes in the vascular wall, which consist
mainly of endothelial cells and vascular smooth muscle cells. Studies have found the involvement of
various exosomal miRNAs and long non-coding RNAs in EC proliferation, inflammation, angiogenesis,
senescence, and apoptosis [92]. For instance, cardiomyocyte-derived exosomal miR-17, miR-19,
and miR-126 promoted the proliferation and migration of ECs, whereas miR-92a, miR-24, and miR-21
inhibited the processes [93]. miR-92a and miR-21 are also implicated in EC inflammation by activating
inflammatory cytokines and chemokines [94]. Exosomal miRNAs can either act as pro-angiogenic
or anti-angiogenic factors. Exosomal miR-125a and miR-106b-5p promote and inhibit angiogenesis,
respectively [95]. Exosomes play a critical role in transferring signaling molecules between ECs and
VSMCs and thereby modulate vascular aging [92].
With aging, the exosomes from bone marrow interstitial fluid were found to have an altered
miRNA profile compared to those from young mice. The miRNA-183 cluster is highly expressed in
exosomes from aged mice [96]. This altered expression could affect the osteogenic differentiation and
also induce stem cell senescence.
10. Exosome Cargo in Senescence
The cells assume a novel phenotype called the senescence-associated secretory phenotype (SASP)
when they become senescent, which is characterized by the secretion of a myriad of factors, including
the release of exosomes [33]. The secreted factors mediate senescence in cells in the immediate vicinity,
which could be detrimental to normal neighboring cells. They do so by blocking growth factor signaling
and thereby contributing to the induction of senescence [36]. High levels of exosomes from senescent
cells are able to modulate the cellular microenvironment. Exosomes are secreted by most cell types
and interact with surrounding cells by introducing regulatory secreted factors or receptors, providing
intercellular communication [97]. Exosomes participate in the traffic of protein, lipids, and RNAs to
neighboring cells, which are necessary for the rapid phenotype variations.
Senescence is associated with the increased release of exosomes, as observed in normal
human fibroblasts [98]. Senescence-associated exosomes were also observed to be released from
human-senescent prostate cancer cells [61]. Exosomes released by EGFR-bearing tumor cells are taken
up by neighboring endothelial cells and can accelerate the growth of the tumor cell [61]. These studies
suggest that senescence-associated exosomes can transfer cargos with both immunoregulatory potential
and genetic information and could influence the microenvironment. Several studies have conferred a
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supporting role for EVs in various diseases and could assist as diagnostic tools. The modulation of
senescent cells, senescence-associated factors, and senescent EVs seems to be a promising strategy for
mitigating age-related diseases [99]. Salient features of exosomes from young and aged individuals are
explained in Table 1 and graphically represented in Figure 3.
Table 1. Salient features of exosomes from young vs. aging individuals.
Exosomes from Young Individual Exosomes from Aged Individual
Normal levels of EV Increased EV secretion
Exosomes do not have an adverse effect on
tissue microenvironment
Exosomes from senescent cells are detrimental to the
tissue microenvironment
Exosomal cargo do not result in any
pathological changes
Exosomal cargo can mediate/accelerate
pathological changes
Normal expression of miRNAs and proteins
Differential expression of miRNAs and proteins could
act as biomarkers for diagnosis of
age-related pathologies
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11. EVs as Potential Diagnostic Markers and Therapeutic Tools for Age-Related Diseases
The EVs can act as biomarkers for various diseases, and they could also indicate the physiological
state of the cell/tissue from which they were released. Exosomes are easily accessible in body fluids
such as blood, plasma, and urine, making them attractive for use as biomarkers. EVs can also be a
representation of the aged phenotype of the cells. EVs has been described as potential non-invasive
biomarkers in cardiovascular and inflammatory diseases [100].
EVs from the bone marrow of aged ice i r iR-96, miR-182, and miR-183, which
are part of cluster miR-183. An miR i ic as shown to increase senescence in bone
marrow stem cells [101]. The miRNAs eli s are found to be critical regulators in many
pathological conditions compared to other cargo molecules such as proteins and lipids [12]. A pilot study
on the possible role of salivary exosomal miRNAs as aging biomarkers revealed miR-24-3p to be a novel
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candidate. The target genes of miR-24-3p activate Mitogen Activated Protein Kinase (MAPK) signaling
pathways involved in inflammatory cytokine and chemokine gene regulation [102]. With aging, the
increased levels of miR-24-3p may contribute to increased susceptibility to age-dependent alterations in
the immune and inflammatory status [103]. Previous studies have examined the relationship between
miRNA profiles and aging. A clinical study reported that serum expression levels of miR-151a-3p,
miR-181a-5p and miR-1248 were significantly lower in aged humans compared to those in young [104].
Yet another clinical study using serum samples identified five down-regulated miRNAs (miR-29b,
miR-106b, miR-130b, miR-142-5p, and miR-340) and three up-regulated miRNAs (miR-92a, miR-222,
and miR-375) with aging [105]. These studies support the notion that circulating miRNAs are useful as
aging biomarkers. The sensitivity of miRNA amplification from biological fluids can be improved by
exosomes isolation, thus making exosomal miRNAs a potential biomarker.
Urinary EVs could be used as biomarkers to identify diabetic nephropathy. Urinary EVs express
high levels of C-megalin, which is an endocytic receptor, and they could serve as a potential
biomarker [106]. The miRNA profiles of urinary EVs has identified the miR192 and miR-15 family to
be differentially expressed, and they could serve as biomarkers.
Diabetic patients have been found to have increased levels of miR-15a-3p in the circulating
exosomes isolated from their blood. The up-regulated miRNA was found to inhibit diabetic wound
repair by activating the NADPH oxidase 5 (NOX5). The inhibition of circulating exosomal miR-15a-3p
was found to accelerate diabetic wound repair and provides a novel target for treating diabetic foot
ulcers [107].
EVs in patients with neurological disorders were found to have altered genetic cargo in the form
of miRNAs and tau proteins, thus acting as disease biomarkers [108]. EVs were found to have increased
levels of p181-tau and p231-tau in the blood of patients with preclinical Alzheimer’s disease [109].
Studies have found that miR-125a-5p, miR-23a-3p, and miR-375 were found to be differentially
expressed and could act as biomarkers for Alzheimer’s disease [110]. Differentially expressed exosomal
miRNAs as biomarkers for aging are detailed in Table 2.
Exosomes, owing to their low immunogenicity and other beneficial effects, could be utilized
for therapeutics or as delivery vehicles. EVs from adipose-derived stem cells have been reported to
improve metabolic homeostasis by inducing the production of anti-inflammatory cytokines [111]. Thus,
EVs from stem cells might have the potential to improve glucose tolerance in diabetic individuals [111].
Table 2. Differentially expressed exosomal miRNAs as biomarkers for aging.
Exosomal miRNA Derived From Function Reference
miR-96, miR-182, miR-183 Bone marrow Increase senescence inbone marrow cells [101]
miR-24-3p Saliva
Inflammatory cytokine
and chemokine gene
regulation
[102]
miR-151a-3p, miR-181a-5p,
miR-1258, miR-29b, miR-106b,
miR-130b. miR-142-5p, miR-340
Serum Down-regulated withaging [104]
miR-92a, miR-222, miR-192 Serum Up-regulated with aging [105]
miR-15 Urine Differentially expressedin diabetic nephropathy [106]
miR-15a-3p Blood Up-regulated in diabeticpatients [107]
miR-125a-5p, miR-23a-3p, miR-375 Blood Differentially expressedin Alzhemier’s Disease [110]
hsa-miR-203-3p,
hsa-miR-4482-3p,hsa-miR-44366b-3p COVID-19 patients
Target S protein involved
in viral replication [112]
hsa-miR-190a-5p COVID-19 patients Target ORF6 involved inimmune suppression [112]
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12. Role of Exosomes in COVID-19 Patients
COVID-19 diseases have by far affected the elderly population more than any other age group,
and people over the age of 65 were found to be more susceptible to the infection (WHO COVID-19
dashboard). People with underlying conditions are prone to succumb to the complications compared
to healthy individuals [113]. COVID-19 infections result in a multitude of damages in almost all
organs—mainly in the lungs and heart.
Recently, researchers found that Angiotensin Converting Enzyme 2 (ACE2) serves as the receptor
for the entry of coronavirus into the cells [114]. Studies also were conducted in elucidating the role
played by exosomes in the spread of the virus. Exosomes were reported to transfer the ACE2 receptor
to recipient cells, and this could also serve as a pathway for the virus internalization and infection.
A study found that the components of viruses could be internalized and transferred via caveolin-1
dependent endocytosis or via other extracellular vesicles [115]. Exosomes from virus-infected cells
were found to elicit immune response in non-infected cells. Understanding the molecular interactions
of miRNA during host–virus interactions will help in the development of effective antiviral therapy.
Studies have investigated the various host–cellular miRNAs that play critical roles in viral biogenesis,
entrance, replication, and infection [112]. Increasing the levels of host miRNAs could block the entry
and propagation of the virus. hsa-miR-203-3p and hsa-miR-4482-3p have been found to target the
Spike (S) protein that plays a role in viral replication, whereas hsa-miR-3672 targets the Envelope (E)
protein that affects viral envelope formation [112].
13. Future Perspectives and Conclusions
The varied nature of the molecules packaged and delivered by exosomes makes it a valuable
biomarker for identifying and tracking disease progression and aging. Understanding the relation
of aging process to age-related diseases is of great clinical importance for the development of novel
therapeutic strategies. The crosstalk of exosomes from the senescent cells with the neighboring cells
and its microenvironment has not been well understood. From the studies, it is clear that senescent
cell-derived exosomes might be a potential target for age-related therapies and can be achieved
by modulating their cargo, mainly miRNAs. Compared to other conventional treatments, the fact
that exosomes are small, potent, and non-living makes them highly attractive bioactive molecules.
Furthermore, exosomes have the additional advantage that these nanovesicles do not invoke an
immune response and also could be used to develop personalized medicines.
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